STOCK TITAN

[144] AtriCure, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) Form 144 discloses a proposed sale of 5,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value listed at $185,000 and an approximate sale date of 08/22/2025. The filer states total shares outstanding of 49,701,415. The 5,000 shares were acquired on 08/22/2025 by stock option exercise from the issuer and paid in cash. The filing also lists a recent sale by the same person: on 08/19/2025 Sven Wehrwein sold 5,000 shares for $180,000. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.

AtriCure, Inc. (ATRC) — il Modulo 144 indica la proposta di vendita di 5.000 azioni ordinarie tramite Morgan Stanley Smith Barney, con un valore di mercato complessivo riportato pari a $185.000 e una data di vendita approssimativa fissata al 22/08/2025. Il dichiarante segnala un totale di azioni in circolazione pari a 49.701.415. Le 5.000 azioni sono state acquisite il 22/08/2025 mediante esercizio di opzione su azioni dall’emittente e saldate in contanti. La registrazione riporta inoltre una vendita recente della stessa persona: il 19/08/2025 Sven Wehrwein ha venduto 5.000 azioni per $180.000. L’avviso contiene la dichiarazione standard che il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate.

AtriCure, Inc. (ATRC) — el Formulario 144 revela una propuesta de venta de 5.000 acciones ordinarias a través de Morgan Stanley Smith Barney, con un valor de mercado agregado indicado de $185.000 y una fecha aproximada de venta del 22/08/2025. El declarante indica un total de acciones en circulación de 49.701.415. Las 5.000 acciones se adquirieron el 22/08/2025 por ejercicio de opciones sobre acciones del emisor y fueron pagadas en efectivo. La presentación también lista una venta reciente por la misma persona: el 19/08/2025 Sven Wehrwein vendió 5.000 acciones por $180.000. El aviso incluye la representación estándar de que el vendedor no tiene conocimiento de información material adversa no divulgada.

AtriCure, Inc. (ATRC) — Form 144는 Morgan Stanley Smith Barney를 통해 5,000 보통주를 매도하려는 제안을 공개하며, 총 시가 가치는 $185,000으로 기재되어 있고 대략적인 매도 예정일은 2025-08-22입니다. 제출인은 총 발행주식수를 49,701,415주로 보고했습니다. 해당 5,000주 는 2025-08-22에 발행사로부터 스톡옵션 행사로 취득되어 현금으로 지불되었습니다. 제출서류에는 동일인이 최근에 행한 매도도 기재되어 있는데: 2025-08-19에 Sven Wehrwein이 5,000주를 $180,000에 매도했습니다. 통지서에는 판매자가 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 표준 진술이 포함되어 있습니다.

AtriCure, Inc. (ATRC) — le formulaire 144 révèle une proposition de vente de 5 000 actions ordinaires via Morgan Stanley Smith Barney, d’une valeur de marché totale indiquée de 185 000 $ et d’une date de vente approximative au 22/08/2025. Le déclarant signale un nombre total d’actions en circulation de 49 701 415. Les 5 000 actions ont été acquises le 22/08/2025 par exercice d’option sur actions auprès de l’émetteur et payées en espèces. Le dépôt mentionne également une vente récente par la même personne : le 19/08/2025, Sven Wehrwein a vendu 5 000 actions pour 180 000 $. L’avis comprend la déclaration standard selon laquelle le vendeur n’a pas connaissance d’informations défavorables importantes non divulguées.

AtriCure, Inc. (ATRC) — Formular 144 offenbart einen geplanten Verkauf von 5.000 Stammaktien über Morgan Stanley Smith Barney mit einem angegebenen Gesamtmarktwert von $185.000 und einem ungefähren Verkaufstermin am 22.08.2025. Der Einreichende gibt insgesamt 49.701.415 ausstehende Aktien an. Die 5.000 Aktien wurden am 22.08.2025 durch Ausübung von Aktienoptionen vom Emittenten erworben und in Bargeld bezahlt. Die Meldung listet außerdem einen kürzlichen Verkauf derselben Person: Am 19.08.2025 verkaufte Sven Wehrwein 5.000 Aktien für $180.000. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen kennt.

Positive
  • Required disclosure elements provided: acquisition date, nature of acquisition, broker, proposed sale date, and aggregate value are all stated.
  • Seller attests that there is no undisclosed material adverse information.
Negative
  • Potential rapid turnover: shares were acquired by exercise on 08/22/2025 with a proposed sale the same date, indicating immediate disposition.
  • Prior sale same size: a sale of 5,000 shares on 08/19/2025 suggests recurring insider sales in a short period.

Insights

TL;DR: Routine insider sale notice; transaction appears compliant with Rule 144 formalities.

The Form 144 documents a small insider sale relative to the company's outstanding shares (5,000 of 49,701,415). The shares were acquired by option exercise and the seller represents no undisclosed material information. Broker details and aggregate market value are provided, and a recent near-identical sale on 08/19/2025 is disclosed. From a compliance standpoint, required acquisition and disposition dates, consideration, and broker are stated, which supports adherence to Rule 144 disclosure requirements.

TL;DR: Small-dollar insider liquidity event; immaterial to market capitalization but relevant for insider activity tracking.

The disclosed proposed sale values the shares at $185,000, and prior sale proceeds were $180,000 for 5,000 shares. Given the company’s 49.7 million shares outstanding, this is a de minimis issuance for market impact. The timing shows immediate exercise-to-sale activity (acquisition and proposed sale dates close together), which may reflect typical insider liquidity after option exercise. No earnings or material corporate events are referenced in the filing.

AtriCure, Inc. (ATRC) — il Modulo 144 indica la proposta di vendita di 5.000 azioni ordinarie tramite Morgan Stanley Smith Barney, con un valore di mercato complessivo riportato pari a $185.000 e una data di vendita approssimativa fissata al 22/08/2025. Il dichiarante segnala un totale di azioni in circolazione pari a 49.701.415. Le 5.000 azioni sono state acquisite il 22/08/2025 mediante esercizio di opzione su azioni dall’emittente e saldate in contanti. La registrazione riporta inoltre una vendita recente della stessa persona: il 19/08/2025 Sven Wehrwein ha venduto 5.000 azioni per $180.000. L’avviso contiene la dichiarazione standard che il venditore non è a conoscenza di informazioni materiali sfavorevoli non divulgate.

AtriCure, Inc. (ATRC) — el Formulario 144 revela una propuesta de venta de 5.000 acciones ordinarias a través de Morgan Stanley Smith Barney, con un valor de mercado agregado indicado de $185.000 y una fecha aproximada de venta del 22/08/2025. El declarante indica un total de acciones en circulación de 49.701.415. Las 5.000 acciones se adquirieron el 22/08/2025 por ejercicio de opciones sobre acciones del emisor y fueron pagadas en efectivo. La presentación también lista una venta reciente por la misma persona: el 19/08/2025 Sven Wehrwein vendió 5.000 acciones por $180.000. El aviso incluye la representación estándar de que el vendedor no tiene conocimiento de información material adversa no divulgada.

AtriCure, Inc. (ATRC) — Form 144는 Morgan Stanley Smith Barney를 통해 5,000 보통주를 매도하려는 제안을 공개하며, 총 시가 가치는 $185,000으로 기재되어 있고 대략적인 매도 예정일은 2025-08-22입니다. 제출인은 총 발행주식수를 49,701,415주로 보고했습니다. 해당 5,000주 는 2025-08-22에 발행사로부터 스톡옵션 행사로 취득되어 현금으로 지불되었습니다. 제출서류에는 동일인이 최근에 행한 매도도 기재되어 있는데: 2025-08-19에 Sven Wehrwein이 5,000주를 $180,000에 매도했습니다. 통지서에는 판매자가 공개되지 않은 중대한 불리한 정보를 알고 있지 않다는 표준 진술이 포함되어 있습니다.

AtriCure, Inc. (ATRC) — le formulaire 144 révèle une proposition de vente de 5 000 actions ordinaires via Morgan Stanley Smith Barney, d’une valeur de marché totale indiquée de 185 000 $ et d’une date de vente approximative au 22/08/2025. Le déclarant signale un nombre total d’actions en circulation de 49 701 415. Les 5 000 actions ont été acquises le 22/08/2025 par exercice d’option sur actions auprès de l’émetteur et payées en espèces. Le dépôt mentionne également une vente récente par la même personne : le 19/08/2025, Sven Wehrwein a vendu 5 000 actions pour 180 000 $. L’avis comprend la déclaration standard selon laquelle le vendeur n’a pas connaissance d’informations défavorables importantes non divulguées.

AtriCure, Inc. (ATRC) — Formular 144 offenbart einen geplanten Verkauf von 5.000 Stammaktien über Morgan Stanley Smith Barney mit einem angegebenen Gesamtmarktwert von $185.000 und einem ungefähren Verkaufstermin am 22.08.2025. Der Einreichende gibt insgesamt 49.701.415 ausstehende Aktien an. Die 5.000 Aktien wurden am 22.08.2025 durch Ausübung von Aktienoptionen vom Emittenten erworben und in Bargeld bezahlt. Die Meldung listet außerdem einen kürzlichen Verkauf derselben Person: Am 19.08.2025 verkaufte Sven Wehrwein 5.000 Aktien für $180.000. Die Mitteilung enthält die übliche Zusicherung, dass der Verkäufer keine nicht offengelegten, wesentlichen nachteiligen Informationen kennt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for ATRC disclose about the proposed sale?

The Form 144 shows a proposed sale of 5,000 common shares via Morgan Stanley Smith Barney with an aggregate market value of $185,000 and an approximate sale date of 08/22/2025.

Who is listed as the seller in the ATRC Form 144 filing?

The filing lists Sven Wehrwein as a seller, with a prior sale on 08/19/2025 of 5,000 shares for $180,000.

How were the shares acquired according to the filing?

The 5,000 shares to be sold were acquired on 08/22/2025 by stock option exercise from the issuer and paid for in cash.

How large is the proposed sale relative to ATRC's outstanding shares?

The filing reports 49,701,415 shares outstanding, so the 5,000-share proposed sale is immaterial to total outstanding shares.

Does the filer assert possession of undisclosed material information?

No; the filer signs a representation that they do not know of any undisclosed material adverse information regarding the issuer.
Atricure

NASDAQ:ATRC

ATRC Rankings

ATRC Latest News

ATRC Latest SEC Filings

ATRC Stock Data

1.79B
47.96M
3.23%
100.57%
4.48%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MASON